This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients (Vi-E)

This study has been completed.
Information provided by (Responsible Party):
Simeone Andrulli, A. Manzoni Hospital Identifier:
First received: May 6, 2008
Last updated: April 10, 2012
Last verified: April 2012

The main purpose of this longitudinal study is to point out the effect of VitabranE on the ESA resistance and on the anemia observed in HD patients undergoing EPO maintenance therapy.

As a secondary purpose we will consider the effect of VitabranE on inflammation and oxidative stress parameters as a function of the changes observed in the anemia parameters.

Condition Intervention Phase
Anemia Device: VitabranE ViE Device: APS-U (Asahi Polysulfone APS) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation Of The Impact Of A New Synthetic Vitamin E-Bonded Membrane On The Anemia And Oxidative Stress In End-Stage Renal Disease (ESRD) Patients

Resource links provided by NLM:

Further study details as provided by Simeone Andrulli, A. Manzoni Hospital:

Primary Outcome Measures:
  • The primary outcome measure will be the ESA resistance index, a combined variable calculated by dividing the weekly ESA dose by haemoglobin level and end-dialysis body weight. [ Time Frame: every other month ]

Secondary Outcome Measures:
  • Inflammatory status (CRP and IL-6) and oxidative stress markers (Vitamin E levels, TAC, Protein carbonyls and AOPP, AGEs). [ Time Frame: every other month ]

Enrollment: 20
Study Start Date: July 2006
Study Completion Date: July 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Vitamin E-bonded polysulfone dialyzer
Device: VitabranE ViE
Polysulfone dialyser with vitamin E alpha-tocopherol
Other Name: Vitamin E-bonded polysulfone dialyzer
No Intervention: 2
Polysulfone dialyzer without vitamin E alpha-tocopherol
Device: APS-U (Asahi Polysulfone APS)
PS Polysulfone dialyser without vitamin E alpha-tocopherol
Other Name: Asahi Polysulfone APS

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female patients, aged ≥ 18, stabilized on BHD for at least 6 months.
  2. Clinical stability during the last 3 months.
  3. Serum Ferritin > 200 mg/L and Transferrin saturation >30%.
  4. Maintenance therapy with epoetin alfa/beta or darbepoetin alfa.

Exclusion Criteria:

  1. One of the following condition in the last 3 months :

    • acute infection
    • vascular access thrombosis
    • ictus cerebri
    • myocardial stroke
    • haemorrhage
    • major surgery
    • haemo-transfusion
  2. Haemoglobinopaty, sickle cell anemia, familial erythroblastic anemia and any other haematological disorder interfering with the aim of the study
  3. Malignancy
  4. Participation to other studies or use of EPO analogues not yet commercialized
  5. pharmacological dosage administration of antioxidant supplements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00687258

Alessandro Manzoni Hospital, Nephrology and Dialysis Department
Lecco, Italy, 23900
Sponsors and Collaborators
A. Manzoni Hospital
Principal Investigator: Francesco Locatelli, MD Nephrology and Dialysis Department - A. Manzoni Hospital
  More Information

Responsible Party: Simeone Andrulli, Simeone Andrulli, MD, A. Manzoni Hospital Identifier: NCT00687258     History of Changes
Other Study ID Numbers: Vit E-Rif01-1
Study First Received: May 6, 2008
Last Updated: April 10, 2012

Keywords provided by Simeone Andrulli, A. Manzoni Hospital:
Oxidative Stress
dialyser membrane
Vitamin E
Erythropoietin responsiveness
Erythropoietin resistance

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Vitamin E
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents processed this record on August 17, 2017